Lapatinib Ditosylate

Lapatinib Ditosylate Basic information
Product Name:Lapatinib Ditosylate
Synonyms:Lapatinib ditosylate;4-QuinazolinaMine, N-[3-chloro-4-[(3-fluorophenyl)Methoxy]phenyl]-6-[5-[[[2-(Methylsulfonyl)ethyl]aMino]Methyl]-2-furanyl]-, 4-Methylbenzenesulfonate (1:2);Lapatinib Ditosylate (Tykerb);GW 572016 ditosylate;GW-572016 ditosylate;GW-572016F;Tykerb Ditosylat;GW-572016F Ditosylate
CAS:388082-77-7
MF:C36H34ClFN4O7S2
MW:753.26
EINECS:1312995-182-4
Product Categories:Inhibitors;Final material;Intermediates & Fine Chemicals;Pharmaceuticals;Tyrosine Kinase Inhibitors
Mol File:388082-77-7.mol
Lapatinib Ditosylate Structure
Lapatinib Ditosylate Chemical Properties
Melting point 240-2420C
storage temp. Sealed in dry,Store in freezer, under -20°C
solubility ≥24.3 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O
form solid
Water Solubility Water: Insoluble
CAS DataBase Reference388082-77-7
Safety Information
Safety Statements 24/25
HS Code 29420000
MSDS Information
Lapatinib Ditosylate Usage And Synthesis
DescriptionLapatinib, an ErB-1 and ErB-2 dual kinase inhibitor, was launched for the treatment of advanced or metastatic HER2 (ErbB2) positive breast cancer in women who have received prior therapy. The drug was discovered and developed by GlaxoSmithKline and is also currently being evaluated for several additional cancer indications.
Chemical PropertiesYellow Solid
UsesLapatinib Ditosylate (GW572016, GW2016, Tykerb, Tyverb) is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM, respectively.
UsesLapatinib Ditosylate is a reversible dual inhibitor of ErbB1 and ErbB2 tyrosine kinases. Antineoplastic.
SynthesisThe synthesis started with Williamson ether synthesis between 2-chloro-4-nitrophenol (58) and 3-fluorobenzyl bromide to give ether 59 in the following scheme; however, no specific yields were provided. Reduction of the nitro group of compound 59 by catalytic hydrogenation over Pt/C and subsequent condensation of the resulting aniline with 4-chloro-6-iodoquinazoline (61) in refluxing i-PrOH afforded compound 62. 4-Chloro-6-iodoquinazoline (61) was prepared by reacting 6-iodoquinazolin- 4(3H)-one (60) with POCl3 in the presence of triethylamine. Compound 62 was subjected to Stille coupling with 5- dioxolanyl-2-(tributylstannyl)furan (63) in the presence of PdCl2(PPh3)2 to give 64. Acidic hydrolysis of acetal 64 using HCl in THF/H2O provided the corresponding aldehyde which was further subjected to reductive amination with 2-(methan-esulfonyl)ethylamine in the presence of sodium triacetoxyborohydride to yield lapatinib. Lapatinib was treated with ptoluenesulfonic acid solution to give lapatinib ditosylate (IX).

Synthesis_388082-77-7

Lapatinib Ditosylate Preparation Products And Raw materials
Olaparib Ruxolitinib Lapatinib iMpurity Lapatinib Impurity 16 Crizotinib Lapatinib impurity L Lapatinib 4-Fluoro Impurity N-De[2-(Methylsulfonyl)ethyl] Lapatinib Erlotinib hydrochloride Lapatinib IMpurity 10 Lapatinib 2-Fluoro Impurity Gefitinib Sorafenib tosylate Lapatinib Lapatinib Ditosylate 3-Chloro-4-(3-fluorobenzyloxy)aniline 2-AMINOETHANETHIOL P-TOLUENESULFONATE Lapatinib

Email:[email protected] [email protected]
Copyright © 2024 Mywellwork.com All rights reserved.